JP2022518292A5 - - Google Patents

Info

Publication number
JP2022518292A5
JP2022518292A5 JP2021543315A JP2021543315A JP2022518292A5 JP 2022518292 A5 JP2022518292 A5 JP 2022518292A5 JP 2021543315 A JP2021543315 A JP 2021543315A JP 2021543315 A JP2021543315 A JP 2021543315A JP 2022518292 A5 JP2022518292 A5 JP 2022518292A5
Authority
JP
Japan
Prior art keywords
epilepsy
composition according
pde4
syndrome
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518292A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014819 external-priority patent/WO2020154520A1/en
Publication of JP2022518292A publication Critical patent/JP2022518292A/ja
Publication of JP2022518292A5 publication Critical patent/JP2022518292A5/ja
Priority to JP2025009888A priority Critical patent/JP2025081323A/ja
Pending legal-status Critical Current

Links

JP2021543315A 2019-01-23 2020-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法 Pending JP2022518292A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025009888A JP2025081323A (ja) 2019-01-23 2025-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962796002P 2019-01-23 2019-01-23
US62/796,002 2019-01-23
PCT/US2020/014819 WO2020154520A1 (en) 2019-01-23 2020-01-23 Methods of treating epilepsy via phosphodiesterase 4 (pde4) inhibition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025009888A Division JP2025081323A (ja) 2019-01-23 2025-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法

Publications (2)

Publication Number Publication Date
JP2022518292A JP2022518292A (ja) 2022-03-14
JP2022518292A5 true JP2022518292A5 (https=) 2023-02-01

Family

ID=71735544

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543315A Pending JP2022518292A (ja) 2019-01-23 2020-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法
JP2025009888A Pending JP2025081323A (ja) 2019-01-23 2025-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025009888A Pending JP2025081323A (ja) 2019-01-23 2025-01-23 ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法

Country Status (6)

Country Link
US (1) US20220098257A1 (https=)
EP (1) EP3914701B1 (https=)
JP (2) JP2022518292A (https=)
CN (1) CN113490739A (https=)
CA (1) CA3127357A1 (https=)
WO (1) WO2020154520A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201911603D0 (en) * 2019-08-14 2019-09-25 Healx Ltd Treatment
EP4001923B1 (en) 2020-11-23 2024-06-05 Roche Diagnostics GmbH Laboratory sample distribution system and laboratory automation system
EP4249607A1 (en) * 2022-03-21 2023-09-27 Warszawski Uniwersytet Medyczny Panel of markers for prediction of epilepsy recurrence in patients with tuberous sclerosis and the uses thereof
CN121022847B (zh) * 2025-10-31 2026-02-06 温州医科大学附属眼视光医院 一种敲除斑马鱼pde6a的sgRNA及其在视觉疾病中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1414841B1 (en) * 2001-07-10 2012-11-14 Lakewood-Amedex, Inc Oligonucleotide-containing pharmacological compositions and their use
US20050164275A1 (en) * 2002-10-18 2005-07-28 Incyte Corporation Phosphodiesterases
WO2006050057A2 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
JP2009509984A (ja) * 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
CA2657093A1 (en) * 2006-07-07 2008-01-10 Steven P. Govek Bicyclic heteroaryl inhibitors of pde4
EP2334180A4 (en) * 2008-09-15 2013-07-03 Univ California RESTRICTING DISEASES WITH A COMBINATION OF ACTIVE SUBSTANCES TO INCREASE THE CONCENTRATION OF EPOXYGENATED FATTY ACIDS AND ACTIVE SUBSTANCES TO INCREASE THE CAMP CONCENTRATION
US20130065936A1 (en) * 2010-05-14 2013-03-14 The Regents Of The University Of California Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors
US20130252924A1 (en) * 2010-11-11 2013-09-26 Akron Molecules Gmbh Compounds and Methods for Treating Pain
US8865723B2 (en) * 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
WO2014083099A1 (en) * 2012-11-30 2014-06-05 Leo Pharma A/S A method of inhibiting the expression of il-22 in activated t-cells
CN107787322B (zh) * 2015-06-17 2023-07-07 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
CN113332292A (zh) * 2016-02-23 2021-09-03 辉瑞公司 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物

Similar Documents

Publication Publication Date Title
JP2022518292A5 (https=)
Grunewald et al. The coronavirus macrodomain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression
Rodier et al. Mitotic arrest in the developing CNS after prenatal exposure to methylmercury.
Dawes et al. Favipiravir (T-705) protects against Nipah virus infection in the hamster model
Messias et al. Structural basis of single-stranded RNA recognition
Tiwari et al. MicroRNA‐induced silencing in epilepsy: opportunities and challenges for clinical application
Hanto et al. The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Clinical, pathologic, and virologic correlation.
McDermott et al. The effect of inhibition of PP1 and TNFα signaling on pathogenesis of SARS coronavirus
Mahanty et al. Pathogenesis of filoviral haemorrhagic fevers
Kubera et al. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission.
Mathieu et al. Lethal Nipah virus infection induces rapid overexpression of CXCL10
Tuddenham et al. Small RNA deep sequencing identifies microRNAs and other small noncoding RNAs from human herpesvirus 6B
Tapescu et al. The RNA helicase DDX39A binds a conserved structure in chikungunya virus RNA to control infection
Castellano et al. Alterations in host DNA methylation in response to constitutive expression of Hop stunt viroid RNA in Nicotiana benthamiana plants
Zhao et al. Analysis of expression profiles of long noncoding RNAs and mRNAs in brains of mice infected by rabies virus by RNA sequencing
Althaus et al. Tailored enrichment strategy detects low abundant small noncoding RNAs in HIV-1 infected cells
JP2018528968A5 (https=)
ATE548454T1 (de) Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis
Sánchez-Carvajal et al. Time series transcriptomic analysis of bronchoalveolar lavage cells from piglets infected with virulent or low-virulent porcine reproductive and respiratory syndrome virus 1
Ghaemmaghami Biology and genetics of PrP prion strains
De Smet et al. Expression of key components of the RNAi machinery are suppressed in Apis mellifera that suffer a high virus infection
Coppo et al. Vibrio cholerae in the horn of Africa: epidemiology, plasmids, tetracycline resistance gene amplification, and comparison between O1 and non-O1 strains.
CA3127357A1 (en) Methods of treating epilepsy via phosphodiesterase 4 (pde4) inhibition
Serra et al. Expression of symptoms elicited by a hammerhead viroid through RNA silencing is related to population bottlenecks in the infected host
US8716257B2 (en) CMV gene products promote cancer stem cell growth